Alkermes earnings date
Alkermes (8AK) Q3 2026 Earnings Report
DE:8AK Q3 2026 EPS Results
- Actual EPS
- EUR 0.08
- Consensus EPS
- -EUR 0.07
- Beat/Miss
- Beat by +EUR 0.16
- One Year Ago EPS
- EUR 0.62
DE:8AK Q3 2026 Revenue Results
- Actual Revenue
- EUR 435.60M
- Expected Revenue
- EUR 420.49M
- Beat/Miss
- Beat by +EUR 15.11M
- YoY Revenue Growth
- +21.80%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 3, 2026
Alkermes's next earnings date is estimated for February 17, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, led by 31% year-over-year growth in proprietary product sales, solid demand across VIVITROL, ARISTADA, LYBALVI, and LUMRYZ, reiterated 2026 guidance, a strong cash position, and substantial progress across the orexin pipeline. The principal challenges were higher reported operating expenses related to pipeline investment and Avadel infrastructure, LYBALVI gross-to-net adjustments, and potential initial competition from new orexin therapies. Highlights significantly outweighed the lowlights.
Alkermes continues to expect full-year VIVITROL net sales in the range of $460 million to $480 million, ARISTADA net sales in the range of $365 million to $385 million, LYBALVI net sales in the range of $380 million to $400 million, total LUMRYZ net sales of $350 million to $370 million, of which Alkermes expects to record $315 million to $335 million, and proprietary portfolio net sales of nearly $1.6 billion in 2026; fourth-quarter proprietary portfolio net sales are expected to be in the range of $400 million to $420 million, LYBALVI gross to net adjustments are expected to be in the 45% range next year and prescription volume is expected to continue to grow nearly 20% year-over-year, LUMRYZ could launch in idiopathic hypersomnia in March 2028, if approved, and six important studies are expected to read out across the orexin portfolio, including VIBRANCE-3 around year-end or in early 2027, BRILLIANCE top line results beginning in mid-2027, ADHD data in the second half of 2027, MDD data in late 2027, and ALKS 4.51 thousand Phase 2 proof of concept data in fatigue toward the end of the year.
- Proprietary Portfolio Sales Increased 31%Third-quarter net sales from Alkermes' proprietary product portfolio increased 31% year over year to $417.3 million, reflecting the addition of LUMRYZ and continued demand growth across the established commercial portfolio.
- Strong Total Revenue and Commercial PerformanceThird-quarter total revenues were $480.1 million, supported by contributions from all four proprietary products and positive underlying demand trends across the commercial business. Manufacturing and royalty revenues were $62.9 million, including $29.5 million from VUMERITY and $26.4 million from the long-acting INVEGA products.
- VIVITROL Demand and Guidance MaintainedVIVITROL third-quarter net sales were $127.6 million, with strong demand driven by penetration in the alcohol dependence market. Sales also benefited from approximately $8 million of gross-to-net favorability, primarily from favorable patient mix. Full-year net sales guidance remained $460 million to $480 million.
- ARISTADA Continued Demand GrowthARISTADA product-family third-quarter net sales were $103.9 million, with demand growth driven by expanded healthcare-provider adoption. Sales also benefited from approximately $7 million of gross-to-net and inventory favorability. Full-year guidance remained $365 million to $385 million.
- LYBALVI Prescription Growth and Expanded AccessLYBALVI third-quarter net sales were $95.9 million, with underlying prescription growth of 18% year over year, supported by new patient starts and broader prescriber adoption. Access expanded to approximately 80% of covered lives, with positive trends in volume demand and prescription fulfillment. Full-year guidance remained $380 million to $400 million.
- LYBALVI Volume Growth OutlookThe company expects LYBALVI prescription volume to continue growing nearly 20% year over year, with acceleration in net sales growth expected to follow as the benefits of expanded payer access are reflected. Beyond 2027, the company expects volume growth and net sales growth to track more closely together.
- LUMRYZ Patient Growth and DemandLUMRYZ third-quarter net sales were $89.9 million, and approximately 4.1 thousand patients were on therapy at quarter end. Growth was driven by strong underlying demand, broader prescriber adoption, increased use among existing prescribers, new enrollments, conversions, and patient persistency. LUMRYZ net sales grew 16% year over year, and management reported no significant pricing pressure.
- LUMRYZ Full-Year Guidance and IH OpportunityFull-year LUMRYZ net sales guidance remained $350 million to $370 million, of which Alkermes expects to record $315 million to $335 million following the mid-February close of the Avadel transaction. The positive Phase 3 REVITALIZE study in idiopathic hypersomnia will support a supplemental NDA submission, with potential launch in March 2028 if approved.
- Proprietary Portfolio and Fourth-Quarter OutlookThe company expects its proprietary product portfolio to deliver net sales of nearly $1.6 billion in 2026 and expects fourth-quarter proprietary portfolio net sales of $400 million to $420 million.
- Solid Profitability and Cash PositionThird-quarter GAAP net income was $16.3 million, EBITDA was $63 million, and adjusted EBITDA was $120.1 million. Alkermes entered the third quarter with approximately $787 million in cash and total investments.
- 2026 Financial Expectations ReiteratedManagement reiterated its 2026 financial expectations across all line items and said performance through the first nine months positioned the company well to deliver against those expectations.
- Orexin Pipeline ProgressThe company described its orexin 2 receptor agonist portfolio as its leading pipeline opportunity. Elixorexan Phase 3 BRILLIANCE studies in narcolepsy type 1 and type 2 are underway, with enrollment progressing and top-line results expected beginning in mid-2027. The VIBRANCE-3 Phase 2 study in idiopathic hypersomnia completed enrollment with approximately 130 participants, with top-line results expected around year-end or in early 2027.
- Positive ALKS 7.29 Thousand ADHD Phase 1b ResultsIn a 50-subject Phase 1b proof-of-concept study in adults with ADHD, ALKS 7.29 thousand was generally well tolerated, with no serious treatment-emergent adverse events and no treatment discontinuations among participants who received the drug. Across two doses, it demonstrated dose-dependent clinically meaningful improvements on exploratory ADHD symptom, disease-severity, cognitive-performance, and information-processing measures.
- ADHD Phase 2 UnderwayThe ALKS 7.29 thousand Phase 2 ADHD study is enrolling adults and is evaluating both once-daily and split-dose regimens, with change from baseline in AISRS total score versus placebo at week 4 as the primary endpoint. Phase 2 data are expected in the second half of 2027.
- Expansion into Major Depressive DisorderAlkermes initiated a 150-patient Phase 2 study of ALKS 7.29 thousand as adjunctive treatment to antidepressants in adults with major depressive disorder who have had a partial response to standard antidepressant therapy. The study includes a prespecified subgroup with excessive daytime sleepiness and is designed to assess depressive symptoms using MADRS and CGIS.
- ALKS 4.51 Thousand Fatigue Program PlannedThe company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study of ALKS 4.51 thousand in fatigue associated with multiple sclerosis or Parkinson's disease, targeting populations with significant unmet need and established fatigue-focused clinical scales.
- Six Orexin Studies Expected to Read OutManagement expects six important studies to read out over the next year across the orexin portfolio, including VIBRANCE-3 in idiopathic hypersomnia, three BRILLIANCE Phase 3 studies in narcolepsy, Phase 2 data for ALKS 7.29 thousand in ADHD and MDD, and Phase 2 proof-of-concept data for ALKS 4.51 thousand in fatigue.
- Complementary Orexin and Oxybate StrategyManagement said healthcare providers and patients view orexins and oxybates as complementary mechanisms. The company plans to generate combination data later in the registration programs to support safe use, physician guidance, and payer support, using LUMRYZ as the comparator.
- Strong Oxybate Market AccessManagement said the access profile for oxybates and LUMRYZ is strong at north of 80% and expects to propose pricing and a reimbursement profile designed to allow broad access to both products.
DE:8AK Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 17, 2027 | 2026 (Q4) | -0.19- | 0.26 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | -0.070.08 | 0.62 | -86.84% (-0.54) | |
| Jul 28, 2026 | 2026 (Q2) | -0.020.00 | 0.61 | -100.00% (-0.61) | |
| May 05, 2026 | 2026 (Q1) | -0.50-0.36 | 0.24 | -250.94% (-0.60) | |
| Feb 25, 2026 | 2025 (Q4) | 0.370.26 | 0.95 | -72.38% (-0.69) | |
| Oct 28, 2025 | 2025 (Q3) | 0.330.62 | 0.65 | -5.00% (-0.03) | |
| Jul 29, 2025 | 2025 (Q2) | 0.340.61 | 0.64 | -4.57% (-0.03) | |
| May 01, 2025 | 2025 (Q1) | 0.230.24 | 0.39 | -38.37% (-0.15) | |
| Feb 12, 2025 | 2024 (Q4) | 0.700.95 | 0.2 | 377.27% (+0.75) | |
| Oct 24, 2024 | 2024 (Q3) | 0.650.65 | 0.54 | 21.01% (+0.11) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


